704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II
0 activities
Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
1 activities
Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
CMV-Specific TCR-T Cells for the Treatment of CMV Reactivation after Allogeneic Hematopoietic Stem-Cell Transplantation
1 activities
CMV-Specific TCR-T Cells for the Treatment of CMV Reactivation after Allogeneic Hematopoietic Stem-Cell Transplantation
Cytogenetic Abnormalities Following CAR T Cell Therapy for B-Cell Malignancies
1 activities
Cytogenetic Abnormalities Following CAR T Cell Therapy for B-Cell Malignancies
Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT
1 activities
Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT
GPRC5D-Targeted CAR T-Cell Therapy CT071 for the Treatment of Refractory/Relapsed Multiple Myeloma
1 activities
GPRC5D-Targeted CAR T-Cell Therapy CT071 for the Treatment of Refractory/Relapsed Multiple Myeloma
Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)
1 activities
Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)
Lymphodepletion with Fludarabine/Cyclophosphamide Shows Higher Complete Response Rates Compared to Bendamustine Prior to CAR-T Therapy
1 activities
Lymphodepletion with Fludarabine/Cyclophosphamide Shows Higher Complete Response Rates Compared to Bendamustine Prior to CAR-T Therapy
Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and...
1 activities
Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies
Phase 1 Study of Trispecific Anti-CD20, Anti-CD19, Anti-CD22 (CAR20.19.22) T Cells for Relapsed, Refractory B-Cell Malignancies
1 activities
Phase 1 Study of Trispecific Anti-CD20, Anti-CD19, Anti-CD22 (CAR20.19.22) T Cells for Relapsed, Refractory B-Cell Malignancies
Phase 1 Trial of CD30-Directed, CCR4 Co-Expressing Chimeric Antigen Receptor T-Cells in Patients with CD30+ Cutaneous T-Cell Lymphomas Refractory to Brentuximab Vedotin
1 activities
Phase 1 Trial of CD30-Directed, CCR4 Co-Expressing Chimeric Antigen Receptor T-Cells in Patients with CD30+ Cutaneous T-Cell Lymphomas Refractory to Brentuximab Vedotin
Reproducible Transient, Significant, Early Donor-Derived T-Cell Expansion, Induced By Pooled Granulocyte Transfusion, during Mismatch T-Cell Replete Cord Blood Transplant - an Optimal Platform for Allogeneic Graft Versus Leukaemia: Results of a Prosp...
1 activities
Reproducible Transient, Significant, Early Donor-Derived T-Cell Expansion, Induced By Pooled Granulocyte Transfusion, during Mismatch T-Cell Replete Cord Blood Transplant - an Optimal Platform for Allogeneic Graft Versus Leukaemia
Safety and Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy Plus Camrelizumab in Patients with Relapsed/Refractory CD30+ Lymphoma
1 activities
Safety and Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy Plus Camrelizumab in Patients with Relapsed/Refractory CD30+ Lymphoma
Safety and Feasibility of Intrathecal Infusion of CD19 and/or CD22 CAR T Cells in r/r B-ALL Patients with CNSL or High-Risk CNS Relapse
1 activities
Safety and Feasibility of Intrathecal Infusion of CD19 and/or CD22 CAR T Cells in r/r B-ALL Patients with CNSL or High-Risk CNS Relapse
The Safety and Efficacy of CD33 CAR-T Therapy for RR AML after HSCT
1 activities
The Safety and Efficacy of CD33 CAR-T Therapy for RR AML after HSCT
WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) – Subgroup Analysis of WU-CART-007 1001
1 activities
WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) – Subgroup Analysis of WU-CART-007 1001
WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results
1 activities
WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results